EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test O... (practices founded EnrichMap to create a ...)

HOME >> BIOLOGY >> TECHNOLOGY

EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity

Date:10/8/2008

practices, founded EnrichMap to create a program dedicated to improving patient compliance. According to Dr. Showalter, "The opposite of treatment www.enrichmap.com [adherence] is not treatment nonadherence. The opposite of treatment adherence is treatment failure. Despite an age-old awareness of healthcare noncompliance, we've made little notable progress in understanding the basic elements of patient noncompliance. The guiding principle of the Emap Profile is that to address noncompliance in the most practical manner, it is far more effective and efficient to change the nature of the medical communications process than to try to change the nature of the patient."

Advance knowledge of a patient's compliance personality enables the healthcare provider/manager to target existing patient management resources using the Emap Compliance Communications Guide to identify specific patient intervention methods. The EMap typology can be viewed as a low-cost extension of the traditional patient history, using a simple questionnaire that can be completed in a few minutes, and the Emap statistical analysis which assigns the patient to one of the six distinct Emap profiles.

EnrichMap is seeking organizations to conduct research projects to demonstrate the benefits that Emap can provide in their own healthcare applications. The Emap program is available to clinicians, clinical trial researchers, healthcare management systems, employee wellness programs, insurance providers, and others invested in improving patient compliance and reducing healthcare costs. For more information about a limited use demonstration study contact Fred Ellman at (262) 764-0652

###

Read the full story at http://www.prweb.com/releases/2008/10/prweb1434244.htm

0

GOOD

Page: 1 2
Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:

EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test O...(practices founded EnrichMap to create a ...)